Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CIPROFLOXACIN Cause Product communication issue? 24 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 24 reports of Product communication issue have been filed in association with CIPROFLOXACIN (Ciprofloxacin). This represents 0.1% of all adverse event reports for CIPROFLOXACIN.

24
Reports of Product communication issue with CIPROFLOXACIN
0.1%
of all CIPROFLOXACIN reports
1
Deaths
7
Hospitalizations

How Dangerous Is Product communication issue From CIPROFLOXACIN?

Of the 24 reports, 1 (4.2%) resulted in death, 7 (29.2%) required hospitalization, and 1 (4.2%) were considered life-threatening.

Is Product communication issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CIPROFLOXACIN. However, 24 reports have been filed with the FAERS database.

What Other Side Effects Does CIPROFLOXACIN Cause?

Drug hypersensitivity (5,266) Arthralgia (3,749) Pain (3,201) Fatigue (3,056) Drug ineffective (2,918) Nausea (2,689) Neuropathy peripheral (2,607) Diarrhoea (2,599) Pain in extremity (2,522) Dyspnoea (2,340)

What Other Drugs Cause Product communication issue?

EVOLOCUMAB (2,341) SEMAGLUTIDE (842) ERENUMAB-AOOE (598) SOMATROPIN (350) PEGFILGRASTIM (333) ETANERCEPT (122) ALBUTEROL (121) NIRMATRELVIR\RITONAVIR (70) DENOSUMAB (68) LEVODOPA (61)

Which CIPROFLOXACIN Alternatives Have Lower Product communication issue Risk?

CIPROFLOXACIN vs CIPROFLOXACIN\DEXAMETHASONE CIPROFLOXACIN vs CIPROFLOXACIN\FLUOCINOLONE ACETONIDE CIPROFLOXACIN vs CISAPRIDE CIPROFLOXACIN vs CISATRACURIUM CIPROFLOXACIN vs CISPLATIN

Related Pages

CIPROFLOXACIN Full Profile All Product communication issue Reports All Drugs Causing Product communication issue CIPROFLOXACIN Demographics